The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.7M data for 1.2M Compounds and 9.0K Targets. Of those, 1,253K data for 577K Compounds and 4.4K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.


If BindingDB is of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

36 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

Article Title
Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability.EBI
Syntrix Biosystems
Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model.EBI
Syntrix Biosystems
Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.EBI
Syntrix Biosystems
Colloidal aggregation causes inhibition of G protein-coupled receptors.EBI
University of North Carolina at Chapel Hill
Chemokine receptor antagonists.EBI
National Heart and Lung Institute
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.EBI
Schering-Plough Research Institute
Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.EBI
Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.EBI
Telik, Inc.
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.EBI
Genzyme Corp.
Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists.EBI
WuXi PharmaTech Co. Ltd
Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.EBI
Schering-Plough Research Institute
Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.EBI
Grupo Uriach
3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists.EBI
Schering-Plough Research Institute
Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.EBI
Schering-Plough Research Institute
Polyoxygenated dysidea sterols that inhibit the binding of [I125] IL-8 to the human recombinant IL-8 receptor type A.EBI
Griffith University
Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.EBI
Schering-Plough Research Institute
3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.EBI
Schering-Plough Research Institute
3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.EBI
C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.EBI
Schering-Plough Research Institute
N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.EBI
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.EBI
Pharmaceutical Research Institute
Synthesis and structure-activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists.EBI
Johnson and Johnson Pharmaceutical Research and Development
Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.EBI
Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity.EBI
Soochow University
Discovery of 1,5-Dihydro-4EBI
Zhejiang University
Structural optimization of aminopyrimidine-based CXCR4 antagonists.EBI
Soochow University
Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead.EBI
Hangzhou Institute of Innovative Medicine
Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.EBI
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.EBI
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.EBI
GSK Pharmaceuticals R & D
2',3'-Dideoxy-N6-cyclohexyladenosine: an adenosine derivative with antagonist properties at adenosine receptors.BDB
Pharmakologisches Institut
Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.BDB
Osaka University of Pharmaceutical Sciences